The efficacy of retreatment with bortezomib relapsed multiple myeloma after auto-HSCT

Abstract

Induction treatment of patients with plasma cell myeloma (PCM) is based on the novel agent: immunomodulatory drugs and proteosome inhibitors followed by autologous hematopoietic stem cell transplantation (auto-HSCT). New clinical trials are emphasised the role of consolidation and maintenance therapy. In this paper is presented a case of adult patient with PCM who was treated with bortezomib-based regimen in induction and relapse after auto-HSCT. Very good partial re­sponse was achieved after each treatment. After second auto-HSCT consolidation with bortezomib was given and depth of response was increased to complete response.